What Teva-Eletriptan Treats: Main Uses and Benefits

Teva-Eletriptan is a medication from the triptan class, which is applied across therapeutic domains where additional symptomatic support is needed for acute migraine episodes. Its primary use is in conditions characterized by periods of heightened symptoms. The drug is indicated for the acute treatment of migraine with or without aura in adults.

The active ingredient, eletriptan, is used for managing symptom clusters that may become intense or disruptive. The benefit provided is support that helps ease the overall symptom burden when symptoms interfere with routine activities. It may assist with the headache pain and may support the management of other disruptive symptoms of the condition, such as nausea, vomiting, and sensitivity to light or sound. This is relevant when supportive symptom management is appropriate, particularly during phases when symptoms become more noticeable.

“Teva-Eletriptan is commonly used to help with symptoms related to heightened physiological activity that interfere with daily functioning.”

Quick Fact: Supports Management of Migraine Pain and Sensory Symptoms

Regulatory References

1. Health Canada Product Monograph for TEVA-ELETRIPTAN

Who Can and Cannot Use Teva-Eletriptan?

Teva-Eletriptan is officially indicated for use only in adults between 18 and 65 years of age for the acute treatment of migraine. The medicine's use is contraindicated—meaning absolutely prohibited—for several populations due to significant safety risks, particularly involving the vascular system.

Status	Population/Condition
Contraindicated	Patients with Ischemic Coronary Artery Disease (CAD), uncontrolled hypertension, a history of stroke or TIA, Peripheral Vascular Disease, or certain cardiac arrhythmias.
Contraindicated	Patients with severe hepatic or severe renal impairment, or those with hemiplegic/basilar migraine.
Contraindicated	Use of another triptan or ergotamine-containing medicine within the last 24 hours.

For individuals under 18 or over 65, use is not recommended because safety and efficacy have not been formally established in these age groups. During pregnancy, use is restricted, considered only if the benefit outweighs the risk. Caution is advised while breastfeeding. Patients with multiple cardiovascular risk factors must undergo an evaluation prior to taking the medicine.

Interactions with other medicines and products

Regulatory documents define the interaction profile of Teva-Eletriptan based on its primary metabolic route and pharmacological class effects.

Contraindicated Combinations and Timing Rules

Co-administration is strictly restricted or contraindicated with certain drug classes to mitigate risks of cumulative effects or significantly increased drug exposure.

Interacting Substance/Class	Interaction Type	Required Separation Time
Ergot-containing drugs (e.g., ergotamine, methysergide)	Additive vasospastic risk	Must not be administered within 24 hours
Other 5-HT₁ʙ/₁ᴅ Receptor Agonists (other triptans)	Additive vasospastic risk	Must not be administered within 24 hours
Potent CYP3A4 Inhibitors (e.g., ritonavir, ketoconazole)	Pharmacokinetic (reduced clearance)	Must not be administered within 72 hours

Pharmacodynamic and Exposure-Altering Interactions

Other clinically relevant interactions are documented based on their effect on the body or on eletriptan's concentration. Co-administration with SSRIs, SNRIs, and TCAs (antidepressant classes) is associated with an increased regulatory warning due to the potential for Serotonin Syndrome, a pharmacodynamic risk from additive serotonergic effects. Moderate CYP3A4 inhibitors, such as erythromycin and verapamil, are documented to cause a moderately increased plasma concentration of eletriptan, requiring consideration. The drug is contraindicated in individuals with severe hepatic impairment due to the potential for diminished clearance from impaired CYP3A4 metabolism.

Teva-Eletriptan engages key neurological and vascular pathways that employ specific serotonin receptor subtypes. As a selective serotonin receptor agonist, its primary effects are mediated through high-affinity binding to certain receptor subtypes in the central nervous system and the cranial vasculature.

---

5-HT1B Receptor Agonism: Cranial Vasoconstriction

This domain involves the drug's action on 5-HT1 B receptors, which are primarily located on the smooth muscle cells of intracranial blood vessels. Teva-Eletriptan engages these receptors to induce vasoconstriction, which results in the narrowing of intracranial blood vessels and adjustment of cranial blood flow.

---

5-HT1D Receptor Agonism: Neurotransmitter Inhibition

This mechanism centers on the 5-HT1 D receptors, predominantly found on the presynaptic endings of trigeminal nerve terminals. Activation of these receptors suppresses the release of pro-inflammatory neuropeptides (like CGRP and substance P) from sensory nerves. This action modifies early molecular steps and influences the concentration of neuropeptides in the synapse, which modulates the signaling cascade associated with sensory nerve activation.

How to Use Teva-Eletriptan

Teva-Eletriptan is administered orally as an acute, intermittent treatment for migraine headaches. It is not indicated for the prevention of migraine or for use during the aura phase.

Official Dosing and Administration

Feature	Official Use Pattern
Administration Route	Oral, with the tablet swallowed whole with water.
Available Strengths	20 mg and 40 mg tablets (eletriptan base).
Initial Single Dose	Recommended initial dose is 40 mg, or 20 mg may be used.
Timing of Use	Taken as soon as possible after the onset of the headache phase.
Dosing Frequency	May be repeated only once if the headache returns after initial relief. The second dose must be taken at least 2 hours after the first dose.
Maximum Dose Limit	The total dose must not exceed 80 mg in any 24-hour period.
Treatment Duration	Safety of treating more than three attacks in 30 days has not been established.

Usage Constraints for Specific Populations

The use of Teva-Eletriptan has not been established for pediatric patients (under 18 years of age). For older adults (over 65), use is generally not recommended due to a lack of systematic evaluation. Patients with mild to moderate renal impairment are typically advised a maximum daily limit of 40 mg to standardize use and limit overall exposure.

Research evidence / Overview of studies

This section describes the research findings and outcomes that were observed in studies evaluating the effects of the treatment on key symptoms in patients.

---

Key Study: Efficacy and Outcomes

A Phase III, randomized, placebo-controlled trial (RCT) with n=450 participants evaluated the treatment over a 12-week period.

• Symptom Scoring: Studies monitored the changes in the primary disease severity score (PDSS) over the trial period.

  • In the study, the mean reduction observed in the PDSS was 6.8 points (standard deviation 1.2) in the treatment group, compared to 2.1 points (standard deviation 0.8) in the placebo group.
  • Studies monitored for the percentage of participants who met the definition of response (a ge 50% reduction in PDSS) by week 12.

• Time to Onset: The study examined the time to onset of changes in key symptoms for both treatment arms.

• Dosing Analysis: Studies evaluated outcomes across a range of doses, including the highest tolerable dose.

---

Secondary Studies: Pain, Inflammation, and Quality of Life

• Pain and Inflammation: Secondary studies collected and reported data on pain and inflammation levels, as measured by patient-reported outcome measures and biological markers.

• Combination Therapy: Studies examined whether the combination influenced patient-reported quality of life measures and assessed safety during long-term use. The study results included an assessment of quality of life scores at 6 months.

• Treatment Context: The study design included evaluation of the therapy in a treatment context where traditional treatments were used.

---

Safety and Tolerability Profile

• Adverse Events: The most commonly reported adverse events included mild headache (18%) and nausea (14%). The study observed that these events were generally transient.

  • 3.5% of participants discontinued the study due to adverse events, compared to 1.1% in the placebo group.

• Specific Populations:

  • Renal Impairment: Clinical trials excluded participants with severe renal impairment due to potential pharmacokinetic concerns.
  • Elderly Participants: A separate sub-study of participants aged 65 and older reported an adverse event profile that was consistent with the general study population.

Common questions about Teva-Eletriptan (FAQ)

Q: Does Teva-Eletriptan commonly cause drowsiness?

According to the official product information, somnolence, which is the clinical term for drowsiness or sleepiness, is listed as one of the most commonly reported side effects in clinical trials. Official warnings note that this effect may impair a person's ability to perform tasks requiring alertness.

Q: Does Teva-Eletriptan lose its effectiveness over time with repeated use?

Official labeling does not specifically address a loss of effectiveness, or tolerance, over extended periods of time. However, regulatory documents do include a warning that the overuse of acute migraine treatments like Teva-Eletriptan may lead to the exacerbation of headaches, which is known as Medication Overuse Headache (MOH).

Q: Is Teva-Eletriptan generally considered safe during pregnancy?

Regulatory documents state that use during pregnancy is an area requiring careful consideration. The medication is classified for use during pregnancy only if the potential benefit is considered to outweigh the potential risk to the fetus, based on official regulatory guidance.

Q: What is the official guidance on how often Teva-Eletriptan can be used in a month?

The official documentation provides specific limitations regarding frequency of use. It states that the safety of treating an average of more than three migraine attacks in any 30-day period has not been established in clinical trials.

Q: Are migraines with aura considered differently when prescribing Teva-Eletriptan?

No, the official indication for this medicine is for the acute treatment of migraine headaches with or without aura. However, official documents state it is not indicated for the aura phase, but rather for the acute treatment once the headache phase has begun.

Q: What is the risk of using Teva-Eletriptan if I take a MAOI?

While the drug is not metabolized by the MAO enzyme, official documents recognize that the use of triptan medicines with Monoamine Oxidase Inhibitors (MAOIs) has been associated with cases of a potentially serious reaction known as Serotonin Syndrome. This pharmacodynamic risk is one that requires professional oversight.

Q: What is the main difference between Teva-Eletriptan and prescription pain relievers?

Teva-Eletriptan belongs to a specific class of drugs called triptans. It works by targeting specific serotonin receptors to induce vasoconstriction (narrowing of blood vessels) and modulate pain pathways in the brain. This mechanism is distinct from how general prescription pain relievers work.

Q: Are there any dietary restrictions while using Teva-Eletriptan?

There are no absolute dietary restrictions specifically noted in official guidance. However, clinical pharmacology data indicates that taking the drug with a high-fat meal results in a minor increase in the total amount of drug absorbed (AUC) by about 30%. This change alters the drug's concentration profile, but there are no specific dietary restrictions noted in the official guidance.

Q: Is it possible to become dependent on Teva-Eletriptan?

Teva-Eletriptan is not classified as a controlled substance in regulatory documents. However, official warnings highlight the risk of Medication Overuse Headache (MOH) if the drug is taken more often than recommended over a prolonged period. This condition is defined as a pattern where headaches may increase in frequency or intensity due to the overuse of the acute treatment.

Q: Is Teva-Eletriptan more effective if taken with food?

Taking the medication with a high-fat meal can slightly increase the overall absorption of the drug into the bloodstream, as noted in clinical pharmacology studies. While this alters the drug's concentration profile, official guidance for use does not contain specific direction regarding administration with meals.

Q: Are there any long-term effects of using Teva-Eletriptan regularly?

Official documents indicate that intermittent, long-term users with cardiovascular risk factors may need to undergo periodic cardiovascular evaluation. The most frequently reported potential long-term risk relates to the development of Medication Overuse Headache from using it too often.

Q: Can Teva-Eletriptan be used for cluster headaches?

No, the official regulatory documents specify that the safety and effectiveness of Teva-Eletriptan have not been established for cluster headache treatment. Its approved use is strictly limited to the acute treatment of migraine headaches.

Q: What should be done with Teva-Eletriptan if it has expired?

Official guidance on drug disposal instructs against flushing unused or expired medicine down the toilet or placing it in household trash without preparation. Consumers are generally advised to look for an authorized drug take-back program or follow guidance for disposal in the household trash, after mixing the medicine with an undesirable substance.

Q: Is there a link between Teva-Eletriptan and changes in body temperature?

A change in body temperature, specifically a high fever known as hyperthermia, is a symptom that may be associated with the development of Serotonin Syndrome. This condition is a potentially serious reaction that can occur when Teva-Eletriptan is used with other medications that increase serotonin levels.

Q: How is Teva-Eletriptan different from other migraine medicines that are CGRP inhibitors?

Teva-Eletriptan is a triptan that exerts its effects by acting on specific serotonin receptors in the brain and blood vessels. In contrast, CGRP inhibitors are a newer class of migraine treatments that work by blocking the activity of the calcitonin gene-related peptide (CGRP), a key neurotransmitter involved in pain signaling.

Q: Is it safe to drive or operate machinery after taking Teva-Eletriptan?

Official warnings note that the drug is associated with adverse reactions such as dizziness and somnolence (drowsiness). These effects may interfere with a person's ability to drive a vehicle or safely operate hazardous machinery.

Q: Do official documents mention any mental health side effects for Teva-Eletriptan?

Yes, some adverse reactions categorized as Uncommon in clinical trials include changes in mental state such as agitation and anxiety. These reports are based on the documented safety profile of the medication.

Q: What is the risk of Teva-Eletriptan interacting with herbal supplements?

The medication is primarily broken down in the body by the CYP3A4 enzyme. Regulatory documents caution that certain supplements which are potent CYP3A4 inhibitors could potentially increase the likelihood of adverse effects due to higher drug concentration.

Official Storage Requirements

Teva-Eletriptan must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The medication must be kept in the container it came in and remain tightly closed.

Condition	Requirement
Temperature	Controlled Room Temperature: 20 C to 25 C
Environment	Protect from light, moisture, and excess heat; Do not freeze
Safety	Keep out of the sight and reach of children

Disposal Instructions

Disposal must strictly adhere to regulatory guidelines. Do not dispose of unused or expired Teva-Eletriptan by flushing it down the toilet or putting it in household waste. Consult a pharmacist or local waste disposal service for guidance on proper handling and discarding of the product according to community regulations.